Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...

After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...

Eight months after snaring an inaugural FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 ...

Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...

With Robert F. Kennedy Jr. slated to take the top spot at the U.S. | RFK Jr. has previously expressed a desire to put a stop ...

Indian drugmaker Lupin is recalling more than 600,000 bottles of the high blood pressure and heart failure drug ramipril due ...

In a contrarian take offered by BMO Capital Markets' Evan Seigerman, the analyst said Robert F. Kennedy Jr. may not rock the ...

After a recent failed showing in a breast cancer subgroup raised doubts around AstraZeneca’s Truqap, the first-in-class AKT ...